Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Amphastar Pharma (AMPH) Tops Q2 EPS by 5c
August 7, 2019 5:02 PM EDTAmphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of $0.08, $0.05 better than the analyst estimate of $0.03. Revenue for the quarter came in at $79 million versus the consensus estimate of $77.61 million.
Dr. Jack Zhang, Amphastars Chief Executive Officer, commented: We are pleased that we have settled... More
